Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Liabilities and Shareholders Equity (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Liabilities and Shareholders Equity readings, the most recent being $949.9 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 21.0% to $949.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.4 billion, a 12.52% increase, with the full-year FY2025 number at $949.9 million, up 21.0% from a year prior.
  • Liabilities and Shareholders Equity hit $949.9 million in Q4 2025 for Amicus Therapeutics, up from $868.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $956.7 million in Q3 2021 to a low of $700.5 million in Q1 2023.
  • Median Liabilities and Shareholders Equity over the past 5 years was $786.7 million (2021), compared with a mean of $800.5 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: decreased 20.61% in 2022 and later increased 21.0% in 2025.
  • Amicus Therapeutics' Liabilities and Shareholders Equity stood at $905.1 million in 2021, then fell by 19.99% to $724.2 million in 2022, then grew by 7.42% to $777.9 million in 2023, then increased by 0.92% to $785.0 million in 2024, then rose by 21.0% to $949.9 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $949.9 million (Q4 2025), $868.8 million (Q3 2025), and $815.3 million (Q2 2025) per Business Quant data.